![conference banner](/images/conference-banner.jpeg)
Abstract
The COVID-19 emergency built pressure on US regulatory bodies to unlock the optional and short pathway of approval for urgently required pharmaceuticals to accomplish population demand for medicinal products within the shortest possible time to limit the suffering and deaths associated with insufficiency of medicinal products in need. During the pandemic, many medicinal products got emergency use authorization (EUA) according to the EUA guidelines provided by the US Food Drug Administration (USFDA). The requirement of abbreviated data submission for EUA attracted many pharmaceutical companies to launch their products as investigational drugs. Clinical data collected from the population is also permitted to get final approval. Comirnaty and Remdesivir got full approval using this regulatory tool. EUA does not ensure the existence of the medicinal product for an extended period. Whenever the emergency is over or the products are no longer needed, the USFDA revokes those according to their legislation. However, after Hydroxychloroquine phosphate and chloroquine sulfate were revoked due to failure to show efficacy, it grabbed the attention of many healthcare stakeholders in the country. It demanded more transparency in the approval pathway of present EUA guidelines. Two attributes, i.e., Current Good Manufacturing Practice exemption and expiry date extension, affect the quality of the medicinal products used during the pandemic. The most critical product distribution data, voluntary in EUA, remarkably endorse the black-marketing and shortage of specific COVID-19-related medicinal products in the pandemic situation. Amendments to the existing guidelines minimize the upcoming public health risk.
Keywords: Emergency use authorization, COVID-19 pandemic, Current good manufacturing practice exemption, Expiry date extension, Emergency use authorization revoke, WHO.
Current Indian Science
Title:Exploration & Outcomes of Emergency Use Authorization during the COVID-19 Pandemic in the United States
Volume: 2
Author(s): Simran Simran, Sabanis Chetan Dushant, Joga Ramesh and Sandeep Kumar*
Affiliation:
- Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
Keywords: Emergency use authorization, COVID-19 pandemic, Current good manufacturing practice exemption, Expiry date extension, Emergency use authorization revoke, WHO.
Abstract: The COVID-19 emergency built pressure on US regulatory bodies to unlock the optional and short pathway of approval for urgently required pharmaceuticals to accomplish population demand for medicinal products within the shortest possible time to limit the suffering and deaths associated with insufficiency of medicinal products in need. During the pandemic, many medicinal products got emergency use authorization (EUA) according to the EUA guidelines provided by the US Food Drug Administration (USFDA). The requirement of abbreviated data submission for EUA attracted many pharmaceutical companies to launch their products as investigational drugs. Clinical data collected from the population is also permitted to get final approval. Comirnaty and Remdesivir got full approval using this regulatory tool. EUA does not ensure the existence of the medicinal product for an extended period. Whenever the emergency is over or the products are no longer needed, the USFDA revokes those according to their legislation. However, after Hydroxychloroquine phosphate and chloroquine sulfate were revoked due to failure to show efficacy, it grabbed the attention of many healthcare stakeholders in the country. It demanded more transparency in the approval pathway of present EUA guidelines. Two attributes, i.e., Current Good Manufacturing Practice exemption and expiry date extension, affect the quality of the medicinal products used during the pandemic. The most critical product distribution data, voluntary in EUA, remarkably endorse the black-marketing and shortage of specific COVID-19-related medicinal products in the pandemic situation. Amendments to the existing guidelines minimize the upcoming public health risk.
Export Options
About this article
Cite this article as:
Simran Simran, Dushant Sabanis Chetan, Ramesh Joga and Kumar Sandeep*, Exploration & Outcomes of Emergency Use Authorization during the COVID-19 Pandemic in the United States, Current Indian Science 2024; 2 : e2210299X269869 . https://dx.doi.org/10.2174/012210299X269869231128100928
DOI https://dx.doi.org/10.2174/012210299X269869231128100928 |
Print ISSN 2210-299X |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3007 |
Call for Papers in Thematic Issues
Advancements in Sustainable Synthesis and Material design towards Greener Chemistry
The thematic issue "Advancements in Sustainable Synthesis and Material design towards Greener Chemistry" explores innovative approaches towards environmentally sustainable practices in organic synthesis and material development. It encompasses a broad spectrum of research, including the design of green synthesis methods that minimize waste and energy consumption, the utilization of renewable ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Theoretical Physicochemical Properties and One-Pot Synthesis of Bis-Azetidinones by [2+2] Ketene – Imine Cycloaddition in the Presence of Montmorillonite
Medicinal Chemistry Modulation of Cytochrome-P450 Inhibition (CYP) in Drug Discovery: A Medicinal Chemistry Perspective
Current Medicinal Chemistry Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management
Current Diabetes Reviews 3D Pharmacophore Based Virtual Screening of A2A Adenosine Receptor Antagonists
Protein & Peptide Letters Random Molecular Fragment Methods in Computational Medicinal Chemistry
Current Medicinal Chemistry Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design 3D Pharmacophore-based Ligand Alignment, Virtual Screening and Molecular Docking Protocols Towards the Discovery of 2-((1H-1,2,4-triazol-1- yl)methyl) Derivatives as Antifungal Inhibitors
Current Bioactive Compounds The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
Current Immunology Reviews (Discontinued) The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets The Biology and Medicinal Chemistry of Epothilones
Current Medicinal Chemistry - Anti-Cancer Agents Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Current Topics in Medicinal Chemistry Pharmacokinetics and Metabolism of Traditional Chinese Medicine in the Treatment of COVID-19
Current Drug Metabolism An Approach to Pharmacological Targets of Pyrrole Family From Medicinal Chemistry Viewpoint
Mini-Reviews in Medicinal Chemistry IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design Synthesis and Evaluation of Chalcone and its Derivatives as Potential Anticholinergic Agents
Letters in Drug Design & Discovery Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)
Current Medicinal Chemistry The Effect of Non-Thermal Microwave-Treated Physiological Solution on Isolated Heart Muscle of Snail
Current Chemical Biology Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters